Medical Device Network on MSN9d
Vivani Medical to spin-off neurostim business Cortigent as public companyVivani was created in 2022 when subdermal drug implant company Nano Precision Medical merged with implantable visual ...
By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
HC Wainwright reduced their FY2024 earnings estimates for shares of Vivani Medical in a note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company ...
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback